Compare TFII & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFII | CYTK |
|---|---|---|
| Founded | 1957 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | TFII | CYTK |
|---|---|---|
| Price | $115.44 | $65.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 17 |
| Target Price | ★ $121.09 | $85.24 |
| AVG Volume (30 Days) | 411.8K | ★ 1.6M |
| Earning Date | 02-17-2026 | 02-27-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $8,047,566,000.00 | $87,211,000.00 |
| Revenue This Year | N/A | $341.94 |
| Revenue Next Year | $2.77 | $50.15 |
| P/E Ratio | $32.29 | ★ N/A |
| Revenue Growth | N/A | ★ 2609.26 |
| 52 Week Low | $72.02 | $29.31 |
| 52 Week High | $131.33 | $70.98 |
| Indicator | TFII | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 52.62 |
| Support Level | $118.46 | $60.05 |
| Resistance Level | $122.88 | $67.10 |
| Average True Range (ATR) | 4.42 | 2.71 |
| MACD | 0.39 | 0.15 |
| Stochastic Oscillator | 41.95 | 62.03 |
TFI International Inc is involved in the provision of transportation and logistics services across the United States, Canada, and Mexico. The company's reportable segments are; Less-Than-Truckload, which derives maximum revenue, Truckload, and Logistics. The Less-Than-Truckload segment engages in pickup, consolidation, transport, and delivery of smaller loads; the Truckload segment deals with full loads carried directly from the customer to the destination using a closed van or specialized equipment to meet customers' specific needs; and the Logistics segment provides asset-light logistics services, including brokerage, freight forwarding, and transportation management, as well as small package parcel delivery. Geographically, the company generates maximum revenue from the United States.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.